Findings

What do systematic reviews say?

22 questions · 22 findings · 2 reviews

No studies found 2 · 9.1%GRADE not reported 0 · 0%Very low 6 · 27.3%Low 9 · 40.9%Moderate 2 · 9.1%High 3 · 13.6%

Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer

Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).

1 finding from 1 review

Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review